Navigation Links
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Date:11/24/2009

signed specifically to address the continuing supply shortage. In the U.S., patients continue to be enrolled in an FDA-approved treatment protocol that has been open since September 2009.

Background on Gaucher disease

Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of glucocerebroside, primarily in macrophages. In this lysosomal storage disorder (LSD), clinical features are reflective of the distribution of Gaucher cells in the liver, spleen, bone marrow, skeleton, and lungs. The accumulation of glucocerebrosidase in the liver and spleen leads to organomegaly. Bone involvement results in skeletal abnormalities and deformities as well as bone pain crises. Deposits in the bone marrow and splenic sequestration lead to clinically significant anemia and thrombocytopenia.

Gaucher disease is the most prevalent LSD. Gaucher disease has classically been categorized into 3 clinical types. Type 1 is the most common; it is distinguished from Type 2 and Type 3 by the lack of early neurological symptoms. Type 1 Gaucher disease is characterized by variability in signs, symptoms, severity, and progression.

Shire's velaglucerase alfa program included the largest and most comprehensive set of Phase III clinical trials conducted to date for Gaucher disease. Over 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies.

Velaglucerase alfa is made using Shire's proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and has a human glycosylation pattern.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the sp
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , Nov. 27, 2014 Research ... "Global Palmitic Acid Industry Report 2014" report ... The Global Palmitic Acid Industry Report ... current state of the global palmitic acid industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:11/27/2014)... BELLINGHAM, Washington, and PITTSFIELD, Massachusetts, USA (PRWEB) November 26, ... pinpoint cancer cells with more accuracy, additive systems to ... improve highway safety by analyzing road conditions are among ... Awards for Photonics Innovation . The awards are sponsored ... photonics , and Photonics Media . , Winners ...
(Date:11/26/2014)... 2014 The North America Thermal ... market for detailed analysis of the growth trends ... reach $616.3 million by 2018, growing at a ... Browse through the TOC of the North America ... idea of the in-depth analysis and industry segmentation ...
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... power supply is an all-purpose power supply , Douglas Drake Michelle Cayouette ... , , , ... Supply, Stratagene has developed the new ... power supply for any, electrophoretic application. The SmartPower 4000 power ...
... , , , ,,,, , A time-saving alternative to conventional library plating and screening ... , , ... , Department of Cell Biology, Cleveland Clinic Foundation, , ... , , ...
... powerful method to detect protein interactions in mammalian ... ,Stratagene , With Stratagenes mammalian two-hybrid assay kit, ... interactions via the activation,of reporter gene expression. This ... functional transcription factor caused by the association of,two ...
Cached Biology Technology:A Versatile Power Supply for All Electrophoresis Applications 2A Versatile Power Supply for All Electrophoresis Applications 3A Versatile Power Supply for All Electrophoresis Applications 4A Versatile Power Supply for All Electrophoresis Applications 5Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 2Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 3Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 4Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 5Low Abundance cDNA Cloned Using Stratagenes Human Universal , cDNA Library 6New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 2New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 3New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 4New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 5New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 6New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 7New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 8New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 9
(Date:11/6/2014)... a predator. Except when that predator runs so fast that ... its size, is the fastest creature on Earth. Some of ... (at about five miles per hour). The fastest human can ... from the tiger beetle, a person would have to hit ... a problem. At peak speeds, everything becomes a blur. They ...
(Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... STATION N.J., PRINCETON, N.J. and JAMAICA PLAIN, Mass., ... (through an affiliate), Medarex, Inc. (NASDAQ: MEDX) and ... Massachusetts Medical School (UMMS) today announced that they ... CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and ...
... Cambridge, UK Wolf-Hirschhorn Syndrome (WHS) is a human ... with WHS have a characteristic set of facial features, ... forehead, and highly arched eyebrows. Other symptoms associated ... and skeletal abnormalities, and the severity of these symptoms ...
... AWRE ) today announced that it has amended and ... of comments and a request from the Securities and Exchange ... range of the tender offer to between $2.20 and $2.60 ... share. Aware has also extended the expiration date for the ...
Cached Biology News:Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 2Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck 3Mouse model provides a new tool for investigators of human developmental disorder 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 3Aware, Inc. Amends and Extends Dutch Auction Tender Offer 4
... marker is specifically designed for two-dimensional ... The four proteins in this marker ... diagonal pattern across a 2D gel. ... 3.8. Mol wt: ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
...
Methylation analysis of gene promoters using bilsulfite treatment of DNA and comparative DNA sequence analysis. Probe design and PCR included....
Biology Products: